Business Wire

CA-TRACKFORCE-VALIANT

29.6.2022 16:02:08 CEST | Business Wire | Press release

Share
Trackforce Valiant Acquires TrackTik Software, Creates the World’s Largest Security Workforce Management Company

Trackforce Valiant , a leading provider of security workforce management solutions, today announced the acquisition of TrackTik Software , one of the most innovative and fastest growing cloud-based security workforce management providers. The combination of these two companies has created a new dominant market leader in providing visibility and control for the physical security workforce.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005064/en/

“We are very excited to welcome TrackTik into the Trackforce Valiant family,” said Trevor Campion, CEO of Trackforce Valiant. “Now more than ever, we believe in the importance of providing the right security solutions for companies of all sizes and business needs. The addition of TrackTik enables us to provide a wide range of technology options that are purpose-built for the unique needs of physical security operations.”

TrackTik was founded in 2013 with the mission of providing a complete set of tools through easy-to-use software and taking the fear out of technology in order to put it to work for security workforce management. From their origins in Montreal, Canada, TrackTik provides solutions to over 35 countries across 6 continents and has been steadily innovating the way companies leverage workforce technology for security operations. The platform provides a full suite of applications, combining the needs of back-office administration to front line security operations.

As a result of this new venture, physical security companies now can leverage the combined best practices of two leading security workforce management providers, providing multiple options for how they can manage security operations. Additionally, the combined technology teams of Trackforce Valiant and TrackTik Software will enable the company to further innovate and enhance their solutions further than any other software provider in the industry.

“The physical security market continues to grow, and with that so does the need for solutions that can grow with them,” said Simon Ferragne, CEO of TrackTik. “This acquisition positions us as the dominant leader for security workforce technology, and we are thrilled to work together to continue our mission to build innovative, leading-edge solutions for our customers.”

Both companies will continue to maintain operations in service of their customers and partners, with Trevor Campion overseeing the combined organization as CEO, and Simon Ferragne, TrackTik’s CEO, entering the role of CTO. Simon Ferragne and TrackTik’s investors, CDPQ Investissements, Georgian, Klass Capital, Inovia Capital, Intercap, and Schauer Ventures have reinvested a portion of their proceeds in the newly combined entity to help foster continued growth in the company. TrackTik will continue to operate and maintain its presence in Quebec as one of Canada’s top small and medium employers. Trackforce Valiant and TrackTik will collaborate on developing and innovating security solutions that include Time and Labor Management, Guard Touring, Incident Management, Dispatch and Mobile Patrol, as well as Billing and Payroll management.

About Trackforce Valiant

Trackforce Valiant is a leader in complete security workforce management solutions. More than 300,000 professionals at over 30,000 customer sites in 45 countries use Trackforce Valiant every day to ensure the delivery of reliable security services, improve operational efficiency and optimally manage their human capital. For nearly 30 years, Trackforce Valiant has provided fully integrated security solutions to its partners and customers. Thanks to its security expertise and state-of-the-art information systems technology, Trackforce Valiant proudly offers the most effective solutions available on the market. Clients include the world's leading security guard service providers, as well as major airports, universities, and corporations across the globe. Additional information is available at https://www.trackforcevaliant.com .

About TrackTik

Founded in 2013, TrackTik is a privately-owned, VC-backed Canadian scale-up of 200+ employees providing a cloud-based workforce management solution in the physical security industry. Headquartered in Montreal, with offices in the UK and a presence in various provinces in Canada and the Netherlands, TrackTik serves 780 customers in more than 35 countries. TrackTik quickly established itself as a market leader with the mission to seamlessly connect humans, workflows, and systems to deliver a better way of working to the physical security workforce. TrackTik’s integrated suite of automated tools fluidly connects frontline operations and back-office management allowing managers to follow the progression of field workers, reduce manual tasks, lower cost, glean actionable insights from data to demonstrate value, promote operational efficiency and boost productivity, job satisfaction, and retention. Additional information is available at https://www.tracktik.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye